Regulatory approval

Published by the Health Canada.

Health Canada approved tepotinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.

This is written in the approval document as:

TEPMETKO (tepotinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.

Citation

EMD Serono, a Division of EMD Inc., Canada. Tepmetko (tepotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074821.PDF. Revised March 2024. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Tepotinib
Sensitivity (+) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Tepotinib